Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ovid Therapeutics Inc.
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
November 12, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Host Investor Event
October 31, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
September 26, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
September 11, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at Upcoming September Investor Conferences
September 04, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
August 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
August 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at Upcoming August Investor Conferences
July 30, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
July 23, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
July 10, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
July 01, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
June 17, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
March 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
December 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 03, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
LGND
OVID
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Tickers
OVID
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.